Literature DB >> 19865088

Therapy: what should we do after the failure of a first anti-TNF?

Chris Deighton.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19865088     DOI： 10.1038/nrrheum.2009.212

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  10 in total

Review 1.  Whither the ACR20?

Authors:  David T Felson
Journal:  J Rheumatol       Date:  2004-05       Impact factor: 4.666

2.  Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.

Authors:  Stanley B Cohen; Paul Emery; Maria W Greenwald; Maxime Dougados; Richard A Furie; Mark C Genovese; Edward C Keystone; James E Loveless; Gerd-Rüdiger Burmester; Matthew W Cravets; Eva W Hessey; Timothy Shaw; Mark C Totoritis
Journal:  Arthritis Rheum       Date:  2006-09

Review 3.  Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities.

Authors:  C P Chung; J L Thompson; G G Koch; I Amara; V Strand; T Pincus
Journal:  Ann Rheum Dis       Date:  2006-02-27       Impact factor: 19.103

4.  New tumour necrosis factor inhibitors for rheumatoid arthritis: are there benefits from extending choice?

Authors:  David L Scott; Andrew Cope
Journal:  Ann Rheum Dis       Date:  2009-06       Impact factor: 19.103

5.  Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry.

Authors:  F Tubach; D Salmon; P Ravaud; Y Allanore; P Goupille; M Bréban; B Pallot-Prades; S Pouplin; A Sacchi; R M Chichemanian; S Bretagne; D Emilie; M Lemann; O Lortholary; O Lorthololary; X Mariette
Journal:  Arthritis Rheum       Date:  2009-07

6.  Treatment of rheumatoid arthritis: we are getting there.

Authors:  Yusuf Yazici
Journal:  Lancet       Date:  2009-06-26       Impact factor: 79.321

7.  Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.

Authors:  Josef S Smolen; Jonathan Kay; Mittie K Doyle; Robert Landewé; Eric L Matteson; Jürgen Wollenhaupt; Norman Gaylis; Frederick T Murphy; Jeffrey S Neal; Yiying Zhou; Sudha Visvanathan; Elizabeth C Hsia; Mahboob U Rahman
Journal:  Lancet       Date:  2009-06-26       Impact factor: 79.321

8.  Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.

Authors:  Kimme L Hyrich; Mark Lunt; Kath D Watson; Deborah P M Symmons; Alan J Silman
Journal:  Arthritis Rheum       Date:  2007-01

9.  Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.

Authors:  Mark C Genovese; Jean-Claude Becker; Michael Schiff; Michael Luggen; Yvonne Sherrer; Joel Kremer; Charles Birbara; Jane Box; Kannan Natarajan; Isaac Nuamah; Tracy Li; Richard Aranda; David T Hagerty; Maxime Dougados
Journal:  N Engl J Med       Date:  2005-09-15       Impact factor: 91.245

10.  Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice.

Authors:  S Bombardieri; A A Ruiz; P Fardellone; P Geusens; F McKenna; K Unnebrink; U Oezer; S Kary; H Kupper; G R Burmester
Journal:  Rheumatology (Oxford)       Date:  2007-05-15       Impact factor: 7.580
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.